Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 1:30 p.m. PT / 4:30 p.m. ET. The presentation will showcase the company's advancements in translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment. Interested individuals can access a live and archived webcast via the company’s website. Adaptive Biotechnologies focuses on developing immune-driven clinical products aimed at treating various diseases including cancer and autoimmune conditions.

Adaptive Biotechnologies presents new data on its clonoSEQ Assay for assessing minimal residual disease (MRD) in patients with multiple myeloma at the ASH Annual Meeting. This FDA-cleared test demonstrates high accuracy in detecting residual cancer cells post-treatment. A study showed that MRD-informed treatment decisions led to a median progression-free survival of 97 months versus 75 months without treatment adjustment (p=0.006). The clonoSEQ Assay not only enhances patient outcomes but also offers potential cost savings, estimated at $916,000 annually per patient.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will present over 35 abstracts regarding its clonoSEQ® Assay at the ASH virtual 62nd Annual Meeting from December 5-8, 2020. This FDA-cleared assay assesses minimal residual disease (MRD) in blood cancers, including chronic lymphocytic leukemia (CLL) and multiple myeloma. Research indicates that MRD measurement correlates with enhanced patient outcomes and healthcare savings. The presentations aim to reinforce clonoSEQ as a vital tool for improving treatment decisions and patient management in hematologic malignancies.

Adaptive Biotechnologies (Nasdaq: ADPT) announced the upcoming launch of T-Detect™ COVID, a groundbreaking T-cell test for past SARS-CoV-2 infections. In a study, T-Detect identified 97% of past infections, significantly outperforming antibody tests which detected only 77%. The research highlights the importance of T-cells in immunity, with findings indicating that some individuals may not develop detectable antibodies. This innovative test aims to provide a more comprehensive understanding of immune responses and will be the first clinical T-cell based diagnostic for COVID-19 infections, set to launch this fall.

Adaptive Biotechnologies (Nasdaq: ADPT) announced a collaboration with GlaxoSmithKline (GSK) to utilize its clonoSEQ® Assay for assessing minimal residual disease (MRD) in GSK's hematology portfolio. The partnership aims to enhance treatment response monitoring and patient outcomes. The clonoSEQ Assay is the only FDA-authorized MRD test for multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia. Adaptive will receive upfront and potential future milestone payments, though specific financial terms remain undisclosed.

Adaptive Biotechnologies reported $26.3 million in revenue for Q3 2020, reflecting a 25% increase from Q2 2020 and a 1% year-over-year rise. Clinical sequencing volume surged 58%, totaling 4,023 tests. While development revenue grew by 5% to $15 million, sequencing revenue fell by 3% to $11.3 million. Operating expenses rose 44% to $63.3 million, contributing to a net loss of $36.7 million, up from $14 million in Q3 2019. The company refrained from providing financial guidance for 2020 due to ongoing COVID-19 uncertainties.

Adaptive Biotechnologies (Nasdaq: ADPT) will release its third-quarter financial results on November 10, 2020, after market close. The company will host a conference call at 1:30 p.m. PT, with a webcast available via the Investors section of its website. Adaptive focuses on leveraging the adaptive immune system's genetics to develop clinical diagnostics and therapeutics, aiming to address diseases like cancer and autoimmune conditions. The firm currently has two commercial products and an expansive clinical pipeline.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in the Morgan Stanley Virtual Healthcare Conference on September 15, 2020, at 10:15 a.m. PT / 1:15 p.m. ET. The company aims to decode the adaptive immune system for disease diagnosis and treatment, boasting two commercial products and a strong clinical pipeline. Interested parties can access a live and archived webcast of the presentation via the company's website. Adaptive Biotechnologies is focused on developing immune-driven clinical products tailored to individual patients.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced participation in the UBS Genomics 2.0 and Medtech Innovations Virtual Summit on August 11, 2020. The management team will engage in a fireside chat at 11:00 a.m. Pacific Time, which will also be available via webcast on the company's website. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to create diagnostics and treatments for diseases, including cancer and autoimmune conditions. The company aims to develop tailored immune-driven clinical products, backed by a robust clinical pipeline and two commercial offerings.